PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group.
PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group. This rebrand expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products and include manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.